GlobeNewswire by notified

Lennart Svantesson will step down as CEO of NAXS AB

Share

This announcement is not an offer of securities for sale in the United States nor in any other country, and securities may not be offered or sold in the United States absent registration or an exemption from registration under U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. Nor does it constitute or form part of, and may not be used for the purposes of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities by any person in any jurisdiction, nor shall it or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment to do so, in which (i) such offer or invitation is not authorised; or (ii) in which the person making such offer or invitation is not qualified to do so; or (iii) to any person to whom it is unlawful to make such offer or invitation.

After more than 10 years as CEO of NAXS AB, Lennart Svantesson has decided to leave his position with the company. He will remain as CEO until a successor is appointed.

The board of NAXS AB thanks him for his long history of service to NAXS.

Contact information:

Lennart Svantesson, CEO

Telephone: +46 73 311 00 11

This information is information that NAXS AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11.45 CET on October 29, 2021.

This press release and further information is available on the Company’s website: www.naxs.se

NAXS AB (publ)
Corp. Reg. No. 556712-2972
Nybrogatan 8
114 34 Stockholm, Sweden
Tel: +46 766 40 00 40, E-mail: info@naxs.se

NAXS is listed on NASDAQ Stockholm. NAXS primarily invests in private equity funds with a Nordic focus, but may also make direct investments or co-investments alongside private equity or other alternative assets funds. In addition, NAXS may, to a limited extent, make other types of investments.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding

STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil

Interim Report - January-March 202426.4.2024 08:00:00 CEST | Press release

STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is available on the Company's website. “2024 has begun strongly with development within the respective portfolio companies proceeding according to plan. The adverse market climate we have previously experienced notwithstanding, our portfolio companies have continued tirelessly to advance the development of tomorrow’s treatments in order that patients can reap the benefits as quickly as possible. We look forward to an increasing tailwind and further progress during the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarter The portfolio company OssDsign reported positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst

Solvay publishes notice of 2024 Annual General Meeting26.4.2024 08:00:00 CEST | Press release

Brussels, April 26, 2024, 8:00am CEST - regulated information Solvay today published materials for its next Ordinary General Shareholders’ Meeting, which will be held on Tuesday May 28, 2024 at the Event Lounge Conference Center, Boulevard Général Wahis 16/F, 1030 Brussels, at 10.30 am CEST. All documents relating to this meeting are now available on www.solvay.com. Shareholders will be asked to vote on a number of resolutions, among others: the approval of the financial statements for the financial year 2023; the approval of a total gross dividend of €2.43 per share; the approval of the revised directors’ remuneration; the renewal of the mandate, for a four-year period, of Ms Aude Thibaut de Maisières, as Director of the company; the appointment of EY regarding the assurance of sustainability information imposed by the EU Directive on sustainability reporting (Corporate Sustainability Reporting Directive); the approval of the change of control provision relating to the issuance of eur

Yara reports increased deliveries, lower prices and reduced GHG emission intensity in 1Q26.4.2024 08:00:00 CEST | Press release

First-quarter EBITDA1 was USD 435 million compared to USD 487 million in first quarter 2023. Net income was USD 16 million (USD 0.07 per share) compared with USD 105 (USD 0.41 per share) a year earlier. First-quarter 2024 highlights: EBITDA1 down 11% from 1Q23 mainly due to lower pricesTotal deliveries up 12% with European deliveries up 37% from 1Q23Reduced GHG emission intensity with implementation of key projectsHealthy demand growth and limited capacity additions indicate tightening supply-demand balance longer term “This quarter's results are down from same quarter last year as increased deliveries are offset by lower prices. Meanwhile, I am pleased to see that our efforts to decarbonize is yielding results. This is crucial to future-proof our business and be able to meet growing demand for low-carbon solutions”, said Svein Tore Holsether, President and Chief Executive Officer. Despite strong urea supply in 2023, prices are generally demand-driven with positive production margins f

Nexstim Plc Business Update Q1 202426.4.2024 08:00:00 CEST | Press release

Press release, Helsinki, 26 April 2024 at 9 AM (EEST) Nexstim Plc Business Update Q1 2024 Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) announces the key highlights of the Company’s business operations during Q1 2024. CEO Mikko Karvinen’s Business Update In line with our main strategic objective, we have continued to focus on profitable net sales growth. The sales of new systems at the beginning of this year has been slow, which is typical considering that hospitals' budgets focus on purchases towards the end of the year. We continued to grow our Diagnostics and Therapy Businesses with new system sales in our key markets in the United States and Europe. Between January and March 2024, we delivered a total of 2 new NBS systems and we are progressing according to our growth plans with our full year 2024 sales pipeline development. We have moved forward with projects that are crucial for the company's strategic competitive advantage, such as the development of our new NBS 6 diagnostics

HiddenA line styled icon from Orion Icon Library.Eye